H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza)):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2014
◆商品コード:GMDHC5788IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:202
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるH5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))の概要
・H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2014’, provides an overview of the H5N1 Infection (Avian Influenza)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
H5N1 Infection (Avian Influenza) Overview 9
Therapeutics Development 10
Pipeline Products for H5N1 Infection (Avian Influenza) – Overview 10
Pipeline Products for H5N1 Infection (Avian Influenza) – Comparative Analysis 11
H5N1 Infection (Avian Influenza) – Therapeutics under Development by Companies 12
H5N1 Infection (Avian Influenza) – Therapeutics under Investigation by Universities/Institutes 17
H5N1 Infection (Avian Influenza) – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
H5N1 Infection (Avian Influenza) – Products under Development by Companies 21
H5N1 Infection (Avian Influenza) – Products under Investigation by Universities/Institutes 25
H5N1 Infection (Avian Influenza) – Companies Involved in Therapeutics Development 26
Akshaya Bio Inc. 26
AlphaVax, Inc. 27
Antigen Express, Inc. 28
Aprogen, Inc. 29
AstraZeneca PLC 30
BioDiem Ltd 31
CEL-SCI Corporation 32
Cocrystal Pharma, Inc. 33
Daiichi Sankyo Company, Limited 34
Emergent BioSolutions Inc. 35
Gemmus Pharma Inc. 36
GlaxoSmithKline plc 37
Green Cross Corporation 38
Hemispherx Biopharma, Inc. 39
iBio, Inc. 40
Immunovaccine, Inc. 41
Inovio Pharmaceuticals, Inc. 42
Johnson & Johnson 43
Kineta, Inc. 44
MacroGenics, Inc. 45
Medicago Inc. 46
Medigen Biotechnology Corporation 47
MedImmune, LLC 48
Microgen Scientific Industrial Company for Immunobiological Medicines 49
Myelo Therapeutics GmbH 50
NanoBio Corporation 51
Nanotherapeutics, Inc. 52
NanoViricides, Inc. 53
Novartis AG 54
OPKO Health, Inc. 55
PaxVax 56
Protein Sciences Corporation 57
REPLICor Inc. 58
SIGA Technologies, Inc. 59
Sirnaomics, Inc. 60
Takeda Pharmaceutical Company Limited 61
TechnoVax, Inc. 62
Vaxart, Inc. 63
Vaxin, Inc. 64
VaxInnate Corporation 65
Vivaldi Biosciences Inc. 66
H5N1 Infection (Avian Influenza) – Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 71
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
A-06 – Drug Profile 77
AE-443p – Drug Profile 78
Alferon LDO – Drug Profile 79
AP-302 – Drug Profile 81
AT-301 – Drug Profile 82
CEL-1000 – Drug Profile 83
DP-C005 – Drug Profile 85
EMER-IT – Drug Profile 86
FBF-001 – Drug Profile 87
flu pandemic (H5N1) vaccine – Drug Profile 88
Flu Vaccine – Drug Profile 89
Gamma-Flu – Drug Profile 90
GelVac – Drug Profile 91
GHB-04L1 – Drug Profile 92
GP-1001 – Drug Profile 93
GP-1002 – Drug Profile 94
GP-1681 – Drug Profile 95
GREFLU/VIE – Drug Profile 97
GSK-1562902A – Drug Profile 98
H5N1 vaccines – Drug Profile 100
HAI-05 – Drug Profile 101
Influ-nRNA – Drug Profile 102
influenza (H5) vaccine – Drug Profile 103
influenza (strain H5N1, H1N1) vaccine – Drug Profile 104
influenza [H5N1] (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant – Drug Profile 105
influenza [strain H5N1] vaccine – Drug Profile 107
influenza [strain H5N1] vaccine – Drug Profile 108
influenza A vaccine – Drug Profile 110
influenza vaccine – Drug Profile 111
influenza vaccine – Drug Profile 113
influenza vaccine – Drug Profile 115
influenza vaccine – Drug Profile 116
influezna [H5N1] (virus like particles) vaccine – Drug Profile 117
Innate Immune Adjuvants – Drug Profile 119
INO-3401 – Drug Profile 120
INO-3510 – Drug Profile 121
INO-3605 – Drug Profile 122
INO-3609 – Drug Profile 123
interferon beta-1a – Drug Profile 124
IPS-07 series – Drug Profile 126
KD-295 – Drug Profile 127
KIB-PCI – Drug Profile 128
MEDI-550 – Drug Profile 129
MG-1109 – Drug Profile 131
Monoclonal Antibodies for Infectious Disease – Drug Profile 133
Monoclonal Antibodies to Inhibit H5 HA for H5N1 Infection – Drug Profile 134
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza – Drug Profile 135
MVAH-5HA – Drug Profile 136
Myelo-001 – Drug Profile 137
NVINF-1 – Drug Profile 138
NVINF-2 – Drug Profile 140
OrniFlu – Drug Profile 141
pandemic influenza [H5N1/H1N1] vaccine – Drug Profile 142
pandemic influenza [H5N1] vaccine – Drug Profile 143
pandemic influenza vaccine [H5N1] – Drug Profile 144
prepandemic influenza vaccine [H5N1] – Drug Profile 145
PXVX-0103 – Drug Profile 147
REP-9 – Drug Profile 149
rintatolimod – Drug Profile 150
Small Molecule for Influenza Virus – Drug Profile 152
Small Molecules to Inhibit Endonuclease for Flu – Drug Profile 153
STP-702 – Drug Profile 154
TVX-003 – Drug Profile 155
UMN-0501 – Drug Profile 156
VAX-161 – Drug Profile 158
VAX-16101C – Drug Profile 159
VGX-3400X – Drug Profile 160
VX-787 – Drug Profile 162
H5N1 Infection (Avian Influenza) – Recent Pipeline Updates 163
H5N1 Infection (Avian Influenza) – Dormant Projects 184
H5N1 Infection (Avian Influenza) – Discontinued Products 187
H5N1 Infection (Avian Influenza) – Product Development Milestones 188
Featured News & Press Releases 188
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 197
Disclaimer 197

[List of Tables]
Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2014 15
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Development by Companies, H2 2014 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Development by Companies, H2 2014 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2014 30
H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H2 2014 31
H5N1 Infection (Avian Influenza) - Pipeline by AlphaVax, Inc., H2 2014 32
H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H2 2014 33
H5N1 Infection (Avian Influenza) - Pipeline by Aprogen, Inc., H2 2014 34
H5N1 Infection (Avian Influenza) - Pipeline by AstraZeneca PLC, H2 2014 35
H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H2 2014 36
H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H2 2014 37
H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H2 2014 38
H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 39
H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H2 2014 40
H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H2 2014 41
H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline plc, H2 2014 42
H5N1 Infection (Avian Influenza) - Pipeline by Green Cross Corporation, H2 2014 43
H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H2 2014 44
H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H2 2014 45
H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H2 2014 46
H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 47
H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H2 2014 48
H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H2 2014 49
H5N1 Infection (Avian Influenza) - Pipeline by MacroGenics, Inc., H2 2014 50
H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H2 2014 51
H5N1 Infection (Avian Influenza) - Pipeline by Medigen Biotechnology Corporation, H2 2014 52
H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H2 2014 53
H5N1 Infection (Avian Influenza) - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014 54
H5N1 Infection (Avian Influenza) - Pipeline by Myelo Therapeutics GmbH, H2 2014 55
H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H2 2014 56
H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H2 2014 57
H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H2 2014 58
H5N1 Infection (Avian Influenza) - Pipeline by Novartis AG, H2 2014 59
H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H2 2014 60
H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, H2 2014 61
H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H2 2014 62
H5N1 Infection (Avian Influenza) - Pipeline by REPLICor Inc., H2 2014 63
H5N1 Infection (Avian Influenza) - Pipeline by SIGA Technologies, Inc., H2 2014 64
H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H2 2014 65
H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 66
H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H2 2014 67
H5N1 Infection (Avian Influenza) - Pipeline by Vaxart, Inc., H2 2014 68
H5N1 Infection (Avian Influenza) - Pipeline by Vaxin, Inc., H2 2014 69
H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H2 2014 70
H5N1 Infection (Avian Influenza) - Pipeline by Vivaldi Biosciences Inc., H2 2014 71
Assessment by Monotherapy Products, H2 2014 72
Assessment by Combination Products, H2 2014 73
Number of Products by Stage and Target, H2 2014 75
Number of Products by Stage and Mechanism of Action, H2 2014 77
Number of Products by Stage and Route of Administration, H2 2014 79
Number of Products by Stage and Molecule Type, H2 2014 81
H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H2 2014 168
H5N1 Infection (Avian Influenza) - Dormant Projects, H2 2014 189
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H2 2014 191
H5N1 Infection (Avian Influenza) - Discontinued Products, H2 2014 192

[List of Figures]
Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2014 15
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 17
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Products, H2 2014 25
Assessment by Monotherapy Products, H2 2014 72
Number of Products by Top 10 Targets, H2 2014 74
Number of Products by Stage and Top 10 Targets, H2 2014 75
Number of Products by Top 10 Mechanism of Actions, H2 2014 76
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 77
Number of Products by Top 10 Routes of Administration, H2 2014 78
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 79
Number of Products by Top 10 Molecule Types, H2 2014 80
Number of Products by Stage and Top 10 Molecule Types, H2 2014 81

【掲載企業】

Akshaya Bio Inc.
AlphaVax, Inc.
Antigen Express, Inc.
Aprogen, Inc.
AstraZeneca PLC
BioDiem Ltd
CEL-SCI Corporation
Cocrystal Pharma, Inc.
Daiichi Sankyo Company, Limited
Emergent BioSolutions Inc.
Gemmus Pharma Inc.
GlaxoSmithKline plc
Green Cross Corporation
Hemispherx Biopharma, Inc.
iBio, Inc.
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
MacroGenics, Inc.
Medicago Inc.
Medigen Biotechnology Corporation
MedImmune, LLC
Microgen Scientific Industrial Company for Immunobiological Medicines
Myelo Therapeutics GmbH
NanoBio Corporation
Nanotherapeutics, Inc.
NanoViricides, Inc.
Novartis AG
OPKO Health, Inc.
PaxVax
Protein Sciences Corporation
REPLICor Inc.
SIGA Technologies, Inc.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Vaxart, Inc.
Vaxin, Inc.
VaxInnate Corporation
Vivaldi Biosciences Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[H5N1感染(トリインフルエンザ)(H5N1 Infection (Avian Influenza)):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆